Gliomas are among the most malignant and most highly vascularized human tumors. We studied the therapeutic action of an angiostatic fragment of human thrombospondin 1 (named TSP1ang) on experimental glioma tumor growth. TSP1ang (enclosing amino acids 167-569) comprised the procollagen-homology domain and the three type I repeats of the original molecule. C6 glioma cells that stably express TSP1ang were generated, and their rate of in vitro growth did not appear to differ from that of C6 cells transfected with an empty plasmid. TSP1ang-expressing C6 cells were then injected either subcutaneously or intracerebrally into nude mice. The resulting tumors appeared to be less vascularized, but unexpectedly started to grow earlier and had a much more invasive phenotype than tumors derived from control C6 cells. They were also much more aggressive, since the mice bearing intracerebral TSP1ang-expressing tumor cells died before day 19 post-implantation, whereas all mice bearing control C6 tumors were alive at this time point. These results indicate that careful attention should be paid at designing smaller fragments from the multimodular angiostatic molecule TSP1 since, as observed in this study, it may unmask protumorigenic properties that counteract its antiangiogenic activity.
Introduction
Oxygen and nutriment bioavailability limits the growth of primary tumors beyond the size of a few mm 3 until they become vascularized. Activation of angiogenesis appears as a required step in tumor progression that permits (but does not guarantee) further growth and metastatic dissemination (Hanahan and Folkman, 1996) . Angiogenesis, the growth of new blood capillaries from a pre-existing vascular network, is switched on in several tumor types by an imbalance in the secretion of angiogenic and angiostatic factors Iruela-Arispe and Dvorak, 1997; Bergers and Benjamin, 2003) . Several studies in a number of experimental tumor models have shown that inhibition of the activity of angiogenic factors (e.g. vascular endothelial growth factor (VEGF)) or increased expression of angiostatic factors (e.g. angiostatin or endostatin) lead to inhibition of tumor growth and metastasis formation (Claffey et al., 1996; Siemeister et al., 1998; Zetter, 1998; Kerbel, 2000) . Several natural angiogenesis inhibitors have been identified, including thrombospondin (TSP)-1 and -2, and fragments of ECM proteins such as arrestin, endostatin, canstatin and tumstatin (Folkman, 1998; Kerbel, 2000; de Fraipont et al., 2001; Kalluri, 2003; Vailhe and Feige, 2003) .
TSP1 is a trimeric multimodular protein that is secreted by a number of different cell types and incorporated into the extracellular matrix (for review, see Bornstein and Sage, 1994; Feige, 2000; Lawler, 2000) . Almost each TSP1 module binds a distinct cell surface receptor, thus providing a variety of biological functions to this large molecule (Sage and Bornstein, 1991; Feige, 2000; Lawler, 2000) . TSP1 regulates cell attachment, proliferation and differentiation in a variety of cell types, and it inhibits in vitro endothelial cell proliferation and migration towards a wide variety of attractants (Volpert et al., 1995) . TSP1 also prevents in vivo neovascularization in the rat cornea (Good et al., 1990) . Two TSP1-derived peptides mimicking this antiangiogenic activity have been described: the NGVQYRN sequence located in the procollagen-like domain and the Mal III peptide (SPWDICSVTCGGGVQRSK) from the third type I repeat (Tolsma et al., 1993; Iruela-Arispe et al., 1999) . This latter sequence, through its binding to CD36 (Asch et al., 1992) , a membrane receptor abundantly expressed by microvascular endothelial cells, triggers endothelial cell apoptosis and inhibition of neovascularization (Jimenez et al., 2000) . A number of studies have reported that overexpression of TSP1 in cancer tumor cell lines (breast and cutaneous carcinomas, fibrosarcoma, glioblastoma) results in a strong decrease of their capacity to form tumors in vivo (Weinstat-Saslow et al., 1994; Bleuel et al., 1999; Streit et al., 1999; Tenan et al., 2000; de Fraipont et al., 2001) . In line with these observations, we recently observed that the level of TSP1 protein is lower in malignant and suspect human adrenocortical tumors than in adrenocortical adenomas (de Fraipont et al., 2000) . Meanwhile, controversial data have been reported regarding the role of TSP1 in tumor growth and metastasis. Based on the observations that neutralization of TSP1 expression inhibits squamous cell and breast carcinoma tumor progression (Castle et al., 1991; Wang et al., 1996) , Tuszynski and colleagues proposed that TSP1 promotes tumor growth.
Malignant gliomas are neuroectodermal tumors characterized by rapid growth, abundant vascularization and tragically poor survival prognostic, because of their resistance to all available therapies (Black, 1991a, b) . Progression of gliomas from low to high grade is correlated with increasing vascular density (Plate and Risau, 1995) . Therefore, inhibition of angiogenesis appears to represent a novel and promising strategy to prevent glioma tumor growth (Stratmann et al., 1997) .
Here, we studied the therapeutic effect of an angiostatic fragment of TSP1 on glioma tumor formation. Despite its demonstrated efficiency, the future use of fulllength TSP1 as an antiangiogenic drug is going to be prohibitive, due to both the very large size of the protein (450 kDa) and its multimodularity, which is susceptible to induce a variety of biological effects. We therefore reasoned that a smaller fragment containing the angiostatic domains might be a more specific and efficient agent. However, we did not want to produce very short peptides since angiostatic peptides are 1000-10 000-fold less biologically active than the intact TSP1 molecule in, for example, endothelial cell migration assays (Tolsma et al., 1993) . For this reason and since trimerization might be important for proper protein folding and activity, we chose to express a trimeric TSP1 fragment (called TSP1ang; Figure 1 ). It contained the two cysteine residues involved in disulfide bridging, the procollagenhomology domain and the three type 1 repeats. The Nterminal heparin-binding domain as well as the type II, type III repeats and the C-terminal domain were absent from this fragment. TSP1ang was expected to be angiostatic, since it contained both angiostatic peptide sequences previously characterized in TSP1 (Tolsma et al., 1993; Vailhe and Feige, 2003) . Injection of C6 glioma cells stably expressing TSP1ang into nude mice generated tumors that were less vascularized but that unexpectedly grew to a larger size and had a much more invasive phenotype than tumors derived from control C6 cells.
Results
Overexpression of a truncated TSP1 protein (TSP1ang) in C6 glioma cells
The rat C6 glioma cell line was chosen with respect to its rapid in vivo growth characteristics and its low level of TSP1 secretion. When implanted ectopically under the skin or orthotopically in the brain of nude mice, C6 cells form fast-growing and highly vascularized tumors. The 1.2 kb-long PvuII-PvuII fragment of the human TSP1 cDNA (1.2 kb) was cloned into the pSecTAG expression plasmid, generating the pSecTAG-TSP1ang plasmid. In vitro translation experiments with this plasmid allowed to detect the expression of a 70 kDa TSP1ang protein tagged with C-terminal polyhistidine and c-myc epitopes (data not shown). This protein extended from human TSP1 amino acids 167-569, and contained the last 65 amino acids of the N-terminal domain, the two cysteine residues involved in trimerization, the procollagen domain and the three type 1 repeats (Figure 1 ). Rat C6 cells were then transfected with either pSecTAG-TSP1ang or an empty pSecTAG plasmid. In all, 12 zeocin-resistant clones, corresponding to control (C1, C2, C3, C4, C5, C6) or TSP1ang-expressing (T1, T2, T3, T4, T5, T6) clones, were selected, amplified and analysed for RNA and protein expression. Results corresponding to clones C1, C2, T1 and T2 are represented in Figure 2 . RT-PCR amplification of a 299-bp-long fragment using transfected C6 cell RNA as a template showed no signal in untransfected cells or in cells transfected with the empty plasmid, and the expected fragment in cells transfected with pSec-TAG-TSP1ang (Figure 2a ). Western blot analysis using a mouse monoclonal antibody against the myc epitope revealed the presence of a 70 kDa protein (under reducing conditions) in pSecTAG-TSP1ang, but not in psecTAG-transfected cells (Figure 2b ). Under nonreducing conditions, two proteins of Mr B150 and 240 kDa were detected in pSecTAG-TSP1ang cells, corresponding probably to dimers and trimers of the 70 kDa monomer (Figure 2b ). In vitro cell proliferation rates of TSP1ang-expressing (T1, T2) and control (C1, C2) clones were determined, and did not show any significant difference (Figure 3a) . A similar doubling time of about 24 h was observed in both cell populations. As peptide sequences from TSP type 1 repeats have been reported to activate latent TGFb (MurphyUllrich and Poczatek, 2000) and as some high-grade glioblastomas have been reported to be growth-stimulated by TGFb (Jennings and Pietenpol, 1998; Piek et al., 1999) , we measured the effects of 5 ng/ml TGFb1 on the proliferation of control and TSP1ang-expressing C6 Figure 1 Schematic representation of TSP1 and TSP1ang proteins. The multimodular structure of TSP1 is made of an NH 2 -terminal domain (NH 2 ), a procollagen homology region (PC), three type I repeats (I), three EGF-like repeats (II) seven Ca 2 þ -binding repeats (III) and a COOH-terminal domain (COOH). TSP1ang lacks most part of the NH 2 -terminal domain, the type II and type III repeats and the C-terminal domain. Polyhistidine and myc epitopes are fused to the NH2-terminus of TSP1ang cells. Under our experimental conditions, TGFb1 reduced the proliferation rate of both cell types by 25% ( Figure 3b ). No modification of the proliferation rates of these two types of cells was also observed under hypoxic conditions (3% O 2 ). We then measured cell migration using the Boyden chamber assay with fetal calf serum and fibronectin as chemoattractants. As shown in Figure 3c , no significant difference was observed between TSP1ang-expressing and control C6 clones. Growth in soft agar was also measured and did not reveal any significant difference in the number, the size and the growth kinetics of control and TSP1ang-expressing clones (data not shown). We then examined whether the expression of TSP1ang modified the expression of VEGF, a major angiogenic cytokine. The results of the RT-PCR analysis shown in Figure 3d indicate that the TSP1ang-expressing cell lines slightly overexpress VEGF-A, as compared to control C6 cells.
In vivo effects of TSP1ang on tumor formation and vascularization
To study the effect of the TSP1 fragment on tumor growth, we implanted stably transfected clones of C6 cells either subcutaneously or intracerebrally into nude mice, and analysed tumor growth formation and tumor vascularization.
The density of tumor microvascularization was examined by histochemical staining of frozen tumor sections using antibodies to two endothelial antigens (CD31 and von Willebrand factor). Optimal sensitivity and accuracy was obtained with anti-CD31 antibodies (data not shown). As shown in Figure 4a , the staining of subcutaneous tumors generated from C6 cells transfected with an empty plasmid allowed to detect a large number of thin and branched microvessels, whereas, in tumors generated from C6 cells expressing TSP1ang, the vessels were much more sparse, larger and less branched. Using computer-assisted image analysis, we could quantify the density and branching of the vascular structures from both subcutaneous and intracerebral tumors (Figure 4b ). The mean vessel density and the degree of vessel branching were decreased around twofold in TSP1ang-expressing tumors as compared to control tumors, and this difference was statistically significant (Po0.05 for subcutaneous tumors and Po0.005 for intracerebral tumors). These observations suggested that TSP1ang has a strong antiangiogenic activity in vivo.
However, the follow-up of in vivo tumor growth provided unexpected results. As shown in Figure 5 , tumors developing ectopically from subcutaneously implanted pSecTAG-TSP1ang-expressing C6 cells grew up to a size of 370.3 cm 3 in 24 days, whereas, . This appeared to result mainly from an accelerated 'take' of the TSP1ang-expressing tumors, since they reached a measurable size 5 days earlier than the control tumors. In addition, histological observation of TSP1ang-expressing tumors revealed abundant necrotic areas that were less frequently observed in control tumors.
To ensure that the protumorigenic effect of TSP1ang did not result from the ectopic site of tumor implantation, we developed an orthotopic model of implantation by injecting tumor cells intracerebrally. In all, 10 4 transfected C6 cells were implanted into the right frontal hemisphere of four nude mice. As brain tumor size could not be readily measured as a function of time, host survival was monitored. As shown in Figure 6 , mice bearing control brain tumors survived significantly longer than animals bearing TSP1ang-expressing tumors. All animals with control C6 tumors were still alive 19 days after injection, whereas animals injected with pSecTAG-TSP1ang-expressing cells showed a median survival time of 14.5 days and were all dead by day 19. The development of the two kinds of tumors was also dramatically distinct. Whereas control C6 cells gave rise to tumors that developed around the injection point, TSP1ang-expressing cells formed highly invasive tumors that spread over the whole brain and eventually overgrew the skull bone. As already observed with subcutaneous tumors, TSP1ang-expressing brain tumors presented a large necrotic area around the injection point.
Discussion
In the present study, we have designed a short fragment of the TSP1 molecule (TSP1ang) which has the following properties: it is homotrimeric, it lacks most Two independent experiments were performed with a total of six clones (three control C1, C2 and C3 and three TSP1ang-expressing T1, T2 and T3 clones) and gave similar results of the heparin-binding domain, does not extend beyond the third type I repeat and it contains the two angiostatic sequences previously identified in TSP1 (Tolsma et al., 1993) . Although TSP1ang expression had no effect in vitro on monolayer cell growth, growth in soft agar and cell migration, implantation of C6 glioma cells that stably expressed this fragment into nude mice generated tumors that were less vascularized than those derived from control C6 cells, but which paradoxically started to grow earlier and reached a larger size. The tumors expressing TSP1ang were very aggressive and infiltrating when implanted intracerebrally. This was observed for several distinct clones and in two independent series of experiments, thus excluding the possibility of a clonal abnormality.
This unexpected observation suggests that the truncation of TSP1 either has exposed a protumorigenic sequence that is normally masked in the entire molecule or has deleted a tumor-suppressor motif. The tripeptidic motif RFK, present within the type I repeats of TSP1ang, was previously reported to have the capacity to activate latent TGFb in long-term cellular assays (Murphy-Ullrich and Poczatek, 2000) . Whether this results from a direct or an indirect effect is still an open question, since delicate molecular techniques such as surface plasmon resonance using purified molecules did not allow to visualize a direct interaction between TSPs and latent TFb (Bailly et al., 1997) . Recent studies have suggested that an indirect mechanism could be responsible for this activation (Grainger and Frow, 2000; Harpel et al., 2001) . We report here that, unlike some other glioblastoma cell lines (Piek et al., 1999) , C6 cell growth is not stimulated but rather inhibited by TGFb in vitro. Enhanced tumorigenesis caused by TSP1ang expression is therefore unlikely to result from an indirect TGFb-mediated effect on tumor cell proliferation. If such an activation of latent TGFb occurs in vivo, it should, however, favor tumor take, as TGFb strongly stimulates extracellular matrix synthesis and prevents its degradation. Using immunohistochemical methods, we did not observe any significant difference in the level of active TGFb expression in established TSP1ang-expressing tumors (analysed 21 days postimplantation) as compared to control C6 tumors. It would be definitely worth, however, to check the levels of active TGFb during the early stages of tumor development.
Truncation of TSP1 down to TSP1ang certainly results in dramatic changes of the bioavailability of the protein. The N-terminal binding sites for heparin, calreticulin and integrin a3b1 and the C-terminal binding sites for avb3 and IAP/CD47 (de Fraipont et al., 2001) are absent from the shortened molecule. The only known binding sites that are preserved are the heparin-binding sequences WXXW and the CD36-binding sequence CSVTCG. The truncated TSP1ang molecule is therefore likely to diffuse much more efficiently around its site of production. If it triggers latent TGFb activation, active TGFb could then be generated in a wider radius around the implanted cells and favor the initial take of the tumor cells more efficiently.
A few other studies have characterized the effects of different truncated TSP1 proteins on tumor growth and vascularization. gp140, a Chinese hamster TSP1 fragment lacking the last 293 N-terminal amino acids, still inhibits angiogenesis in vitro and in vivo (Good et al., 1990) , but its action on tumorigenesis was not studied. On its own, the 25 kDa N-terminal fragment of TSP1 was recently shown to increase MMP2 activity, to decrease TIMP2 production and to promote in vivo angiogenesis (in the rabbit cornea assay) (Taraboletti et al., 2000) . The N-terminal deletion of TSP1 is thus probably not responsible for the aggressive phenotype of TSP1ang-expressing tumors.
In contrast, expression of TH50, a human TSP1 fragment lacking the last 80 C-terminal amino acids, in MDA-MB 435 breast carcinoma cells, was shown to stimulate tumor growth in nude mice, whereas it did not significantly modify tumor microvessel density (Weinstat-Saslow et al., 1994) . Although a marked effect on tumor angiogenesis was not observed in this situation, the phenotype was reminiscent of the one we observed in tumors derived from TSP1ang-expressing C6 cells. This suggests that C-terminal rather than Nterminal TSP1 truncation may be responsible for the appearance of a protumorigenic effect. The integrinassociated protein (IAP/CD47) is the only characterized TSP1 receptor that binds to sequences located in the Cterminal globular domain (Gao et al., 1996) . Interaction of the TSP1 C-terminus with IAP/CD47 promotes apoptosis in quiescent human umbilical vein endothelial cells (Freyberg et al., 2000) . The C-terminal deletion of TSP1 might thus promote tumor cell survival if C6 cells respond to TSP like endothelial cells do.
Conflicting results have been reported regarding the function of TSP1 in tumor progression. Whereas underexpression of TSP1 has been correlated with cancer progression in several human tumors (Grossfeld et al., 1997; Bunone et al., 1999; de Fraipont et al., 2000 de Fraipont et al., , 2001 , several studies have also reported the association of increased TSP1 expression with increased malignancy (Ohta et al., 1999; Yoshida et al., 1999; de Fraipont et al., 2001 ). In human gliomas, studies have been restricted to a variety of tumor cell lines, and have shown that expression of TSP1 is strongly decreased in high-grade tumor cell lines Tenan et al., 2000) . Tuszynski et al. (1993) described a 50 kDa membrane receptor (named CBP) that specifically binds the CSVTCG sequence in the type 1 repeats of TSP1 and is overexpressed in several types of invasive human tumors (Wang et al., 1996) . Anti-CBP antibodies inhibited tumor growth in mice inoculated with breast cancer cells. One can thus hypothesize that conformational changes are induced in TSP1ang by the N-and C-terminal truncations and the CSVTCG sequence becomes more accessible to the CBP receptor. Indeed, the activity of the intact TSP proteins and their derived peptides appears to be very dependent on their conformation. For example, engagement of the a3b1 integrin by a soluble TSP-1 peptide inhibits endothelial cell proliferation and angiogenesis, whereas the same peptide stimulates endothelial cell proliferation when immobilized (Chandrasekaran et al., 2000) . Further studies are required in order to determine whether shorter TSP1 fragments than TSP1ang still trigger tumor invasiveness. Since synthetic aliphatic peptides have been shown to be antiangiogenic, deletion of the cysteine residues involved in trimerization should not alter the antiangiogenic activity, but may dramatically change the overall conformation and therefore the protumorigenic activity of the recombinant protein fragment.
An interesting observation in this study is that reduced vascularization (as indicated by reduced vascular density and presence of necrosis in TSP1ang-expressing tumors) is not sufficient to prevent tumor growth. This suggests that, for an antiangiogenic therapy to be efficient, the vascularization has not only to be lowered, but also has to be inhibited completely. One should remember also that, despite their numerous qualities, the experimental models of gliomas are still a pale imitation of the human pathophysiological situation. In human gliomas, tumor progression develops over a longer period of time and interaction of glioma cells with host endothelial cells, immunological cells and extracellular matrix plays a crucial role (Goldbrunner et al., 2000) .
In conclusion, our results indicate that the use of TSP fragments to inhibit tumor angiogenesis and tumor growth requires cautious preclinical evaluation, since some of these fragments, such as the one studied here, may induce tumor growth instead of tumor regression. Safer shorter fragments will have to be designed to avoid this problem. The recent observation that tumor cells become progressively resistant to the angiostatic action of TSP1 (Filleur et al., 2001 ) is a second major inconvenience for the use of TSP1 fragments in antiangiogenic therapy. However, a better knowledge of the biological mechanisms responsible for these effects may help to optimize the beneficial potential of the angiostatic domains of TSP1 and TSP2.
Materials and methods

Cell culture
The rat glioma cell line C6 (American Type Culture Collection CCL 107) was maintained in DMEM supplemented with 10% (v/v) fetal calf serum, 100 U/ml penicillin G and 100 mg/ml streptomycin (Life Technologies, Cergy-Pontoise, France).
Plasmids
The 1.2 kb PVuII hTSP1 fragment, isolated from p6STXE/ SK þ (a generous gift from Dr W Frazier, Washington University School of Medecine, St Louis, MO, USA), was ligated into the PVuII site of the CMV promoter-driven eucaryotic expression vector pSecTAG2 (Invitrogen, Groningen, Netherlands), generating the plasmid pSecTAG-TSP1ang. The TSP1ang cDNA was inserted between the IG k-chain signal sequence and myc and polyhistidine tags. The presence and proper orientation of the hTSP1 fragment were verified by restriction analysis and DNA sequencing. The translated fusion protein produced from this plasmid was analysed by Western blotting using a mouse monoclonal antibody against the c-myc epitope (Roche, Meylan, France).
Cell transfection
C6 cells were transfected with 10 mg of pSecTAG-TSP1ang expression plasmid or pSecTAG2 control vector, using the liposomal transfection reagent DOTAP (Roche) according to the manufacturer's directions. After 24 h, zeocin (400 mg/ml) (Invitrogen) was added and single clones were isolated after 2-3 weeks of selection. For each condition, six clones (named C1, C2, C3, C4, C5, C6 for pSecTAG-transfected cells and T1, T2, T3, T4, T5, T6 for pSecTAG-TSP1ang-transfected cells) were amplified and characterized for TSP1ang expression. Three of them were further utilized for cell-and tumor-growth experiments.
RNA isolation and RT-PCR analysis
Total RNA was extracted from cultured cells or tumor specimens, using the RNAgents s total RNA isolation system (Promega, Charbonnie`res les Bains, France) according to the manufacturer's recommendations, and reverse-transcribed into cDNA using Superscriptt II Reverse Transcriptase (Life Technologies). The following PCR primers were synthesized by OligoExpress (Paris, France): RPL27 5 0 -ACAGGTTGCT TAGGGAGCTTCC-3 0 and 5 0 -GGTTACTTCGGCAAAGT TGGC-3 0 , TSP1 5 0 -TCCCCATCCAAAGCGTCTTCAC-3 0 and 5 0 -GACGACTACGTTTCTGTACCCCTC-3 0 , VEGF-A 5 0 -AATGATGAAGCCCTGGAGTGC-3 0 and 5 0 -CTTTCGT TTTTGACCCTTTCCC-3 0 . The RT-PCR amplification reactions were performed as follows. For RPL27: 5 min at 921C, 25 cycles comprising 1 min at 921C, 1 min at 551C and 1 min at 721C, and a final extension at 721C for 5 min; for TSP1: 5 min at 921C, 30 cycles comprising 1 min at 921C, 1 min at 581C and 1 min at 721C, and a final extension at 721C for 5 min; for VEGF-A: 5 min at 941C, 30 cycles comprising 1 min at 941C, 1 min at 551C and 1 min at 721C, and a final extension at 721C for 5 min. The RT-PCR products were analysed by 2% agarose gel electrophoresis. DNA Molecular Weight Markers X (Roche) were used as a standard.
Cell-proliferation assay
To assess the effects of TSP1ang on cell proliferation, 200 cells were plated in 96 well plates in triplicate and grown in DMEM supplemented with 10% fetal calf serum for 7 days. On each day, the number of living cells was determined in triplicate wells using the WST1 reagent kit (Roche).
Soft-agar growth assay
Six-well plates were coated with a bottom layer of agar (DMEM, 10% fetal calf serum, 0.5% agar; 4 ml/well). After this bottom layer was gelified, a top layer of agar (DMEM, 10% fetal calf serum, 0.35% agar; 2 ml/well) containing 2 Â 10 3 tumor cells was added to each well, and the cultures were incubated at 371C in a 5% CO 2 atmosphere. After 14 days of culture, the colonies were stained with 0.005% Crystal violet and counted.
Cell migration assay
Cell migration was measured with a modified Boyden chamber assay. FALCON s HTS Fluoroblockt inserts (Becton Dickinson, Pont de Claix, France) were assembled in 24-well plates. The lower chambers were filled with DMEM containing 2% fetal calf serum and 100 mg/ml fibronectin as chemoattractants. Cells (5 Â 10 4 ) were prelabeled with DiI (5 mg/ml; Chemicon) and added to the upper chamber in medium supplemented with 2% fetal calf serum. The plates were incubated at 371C during 9 h. Every 3 h, cells that had migrated to the lower surface were counted on a fluorescence plate reader.
Subcutaneous and intracranial tumorigenesis assay
All animal work was carried out in the CEA animal facility, in accordance with local and governmental guidelines. The stably transfected clonal cells were grown in complete medium containing 400 ml/ml zeocin (Invitrogen), harvested, counted and resuspended at a final concentration of 10 5 cells/ml in serum-free DMEM. Cells (2 Â 10 4 ) were injected subcutaneously over the four limbs of nude mice (Swiss nu/nu, Charles River, L'Arbresle, France) and tumor growth was monitored over a period of 24 days. The smallest and largest tumor diameters were measured every day with a caliper, and tumor volumes were calculated using the formula: volume ¼ 4/3 p Â (1/ 2 smallest diameter) 2 Â 1/2 Â larger diameter. Tumor sizes are reported as mean volumes7s.d., and statistical differences between groups were determined using Student's t-test.
C6 clonal cells (10 4 cells in 10 ml of serum-free DMEM) were injected into the right frontal hemisphere of nude mice using a stereotaxic fixation device. Mice were monitored daily and differences in survival times were determined.
Immunohistochemistry
To determine the degree of tumor angiogenesis, frozen sections of intracerebral or subcutaneous tumors were stained with a monoclonal antibody against mouse CD31 (Pharmingen, Montrouge, France), which specifically stains endothelial cells.
Frozen sections, 20 mm thick, were fixed in 4% paraformaldehyde for 10 min at room temperature. After three PBS washes, sections were incubated in 3% hydrogen peroxide during 20 min at room temperature and then saturated in PBS containing 3% BSA during 30 min. Sections were incubated overnight at 41C with the first antibody diluted 1/500 in PBS, BSA 3%. After three washes with PBS during 15 min, sections were incubated with biotinylated secondary antibody (Sigma, St Louis, MO, USA) for 60 min at room temperature, rinsed three times for 10 min with PBS and stained with diaminobenzidine (Valbiotech, Paris, France). The slides were dried and mounted with Lemonvitrex (Carlo Erba, Val de Rueil, France). In parallel, other sections were stained with hematoxylin. Vessel density was recorded as the number of CD31-positive structures per field ( Â 10 magnification). In all, 10 fields per section were randomly selected from non-necrotic areas of tumors. Statistical differences between groups were determined using Student's t-test.
